Nykode Therapeutics ASA
OTC:VACBF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Nykode Therapeutics ASA
OTC:VACBF
|
NO |
|
Far East Consortium International Ltd
F:FET
|
KY |
|
E
|
Estee Lauder Companies Inc
F:ELAA
|
US |
|
JCDecaux SE
PAR:DEC
|
FR |
|
Cactus Inc
F:43C
|
US |
|
S
|
Siam Steel Service Center PCL
SET:SSSC
|
TH |
Intrinsic Value
Is VACBF undervalued or overvalued?
See the intrinsic value estimate for Nykode Therapeutics ASA and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
VACBF looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with VACBF’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Nykode Therapeutics ASA Does
Nykode Therapeutics is a biotechnology company that develops DNA-based vaccines and immunotherapy candidates for cancer and infectious diseases. Its main work is to design vaccine programs that train the immune system to recognize specific targets, then move those candidates through research and clinical testing. The company is not a drug seller in the usual sense; it is building a pipeline of experimental medicines around its core vaccine technology.
- Headquarters
- Norway NO
- Employees
- 135
- IPO date
- Jan 27, 2020
Revenue & Expenses Breakdown
Nykode Therapeutics ASA
Earnings Waterfall
Nykode Therapeutics ASA
The intrinsic value for Nykode Therapeutics ASA (VACBF) under the Base Case is hidden USD.
Compared with the current market price of 0.4542 USD, the stock appears hidden.